Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Capillaries

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Capillaries. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-004972-49 Sponsor Protocol Number: CLFG316X2202 Start Date*: 2016-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant ass...
    Medical condition: Transplant associated microangiopathy (TAM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10050444 Microangiopathy NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005328-13 Sponsor Protocol Number: ALXN1210-TMA-315 Start Date*: 2021-10-04
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated wi...
    Medical condition: thrombotic microangiopathy associated with a trigger
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    20.0 10047065 - Vascular disorders 10062198 Microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005147-10 Sponsor Protocol Number: KORPO - 0104 Start Date*: 2005-01-31
    Sponsor Name:KORPO S.R.L.
    Full Title: Randomised controlled clinical trial to evaluate the efficacy of a sodium salicylate hydroglyceric solution used at different concentrations in the aesthetic and functional sclerotherapy of veins, ...
    Medical condition: Patients with ecstatic vessels in inferior limbs
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057165 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004613-24 Sponsor Protocol Number: 01 Start Date*: 2016-05-30
    Sponsor Name:Radboudumc
    Full Title: Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial.
    Medical condition: (very early) systemic sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006233-40 Sponsor Protocol Number: CRFB002ADE04 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology, Bonn University
    Full Title: Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every ...
    Medical condition: Typical findings in Type 2 idiopathic macular telangiectasia (type2-IMT)are parafoveal ectatic capillaries, The disease is characterized by a slow decrease in visual acuity, reading difficulties an...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064761 Parafoveal telangiectasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003193-14 Sponsor Protocol Number: DIAMOND Start Date*: 2017-10-03
    Sponsor Name:Department of Ophthalmology, MUW
    Full Title: Disease-modification under treatment with aflibercept in advanced diabetic retinopathy - A pilot study
    Medical condition: proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002462-12 Sponsor Protocol Number: NL70085.058.19 Start Date*: 2019-10-22
    Sponsor Name:Leiden Universitair Medisch Centrum
    Full Title: Imaging tumor angiogenesis using [18F]-PSMA-1007 PET/CT in patients with colon and gastric cancer.
    Medical condition: Colon and gastric cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003799-63 Sponsor Protocol Number: BAY1193397/17500 Start Date*: 2017-03-29
    Sponsor Name:Bayer AG
    Full Title: A randomized, single blind, threefold crossover, single center study to assess the safety and the effects of 1 mg and 5 mg BAY 1193397 in comparison to placebo on skin capillary blood flow and tran...
    Medical condition: Treatment of diabetic foot ulcer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10012684 Diabetic peripheral vascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002796-28 Sponsor Protocol Number: CEASESTIFFNESS Start Date*: 2016-04-12
    Sponsor Name:University Medical Center Groningen (UMCG)
    Full Title: The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers.
    Medical condition: Systemic sclerosis (SSc) is characterized by skin fibrosis and visceral disease, mainly of the lungs, kidneys and the heart, accompanied by microvascular damage ultimately leading to digital ischem...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000726-11 Sponsor Protocol Number: SHP616-302 Start Date*: 2016-03-08
    Sponsor Name:Shire Viropharma, Inc.
    Full Title: A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney t...
    Medical condition: Acute Antibody Mediated Rejection (AMR) in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013459-31 Sponsor Protocol Number: AT1001-011 Start Date*: 2009-12-10
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS
    Medical condition: Fabry Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000487-11 Sponsor Protocol Number: CRFB002D2201 Start Date*: 2005-09-30
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the...
    Medical condition: Male and female patients >18 years of age with either type 1 or type 2 diabetes mellitus with stable HbA1c levels between 6.5 and 10% and diabetic macular edema with center involvement in at least ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003479-20 Sponsor Protocol Number: 2011/433 Start Date*: 2013-04-15
    Sponsor Name:Handkirurgiska kliniken, Universitetssjukhuset Örebro
    Full Title: Lateral humerus epicondylitis- a clinical, muscle morpological, muscle metabolical and functional evaluation of a new model for treatment.
    Medical condition: Chronic lateral humerus epiconcylitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004863 10024032 Lateral epicondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001719-65 Sponsor Protocol Number: CALC-SSc Start Date*: 2018-12-10
    Sponsor Name:University Medial Center Groningen
    Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study
    Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005303-32 Sponsor Protocol Number: AC-052-438 Start Date*: 2012-03-05
    Sponsor Name:Actelion Pharmaceuticals Nederland bv
    Full Title: Effects of bosentan in a HOMogenEous population of SSc subjects with an early or active SSc nailfold capillaroscopic pattern (HOME II)
    Medical condition: Digital Ulcera in Systemic Sclerodermia patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10053400 Endothelin increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003056-21 Sponsor Protocol Number: WIRE Start Date*: 2020-02-07
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.
    Medical condition: Surgically resectable renal cell cancer (Stage M0/M1)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004583-22 Sponsor Protocol Number: 548.12 Start Date*: 2012-10-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: Verification of the effectiveness of intravenous sildenafil compared to other pulmonary vasodilators used in the test vessel reactivity of pulmonary
    Medical condition: Subjects in children with congenital heart disease surgery or not, with echocardiographic signs of pulmonary hypertension followed at the Pediatric Cardiology Centre of the Mediterranean or reporte...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10047065 Vascular disorders SOC
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003921-13 Sponsor Protocol Number: 12/0368 Start Date*: 2013-06-07
    Sponsor Name:University College London
    Full Title: COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE).
    Medical condition: Pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001032-11 Sponsor Protocol Number: OMS721-TMA-001 Start Date*: 2014-09-30
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombo...
    Medical condition: Three forms of thrombotic microangiopathies (TMA): - atypical hemolytic uremic syndrome (aHUS) - hematopoietic stem cell transplant (HSCT)-associated TMA - thrombotic thrombocytopenic purpura (TTP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043645 Thrombotic microangiopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002057-11 Sponsor Protocol Number: OMS721-HUS-002 Start Date*: 2017-09-15
    Sponsor Name:Omeros Corporation
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents.
    Medical condition: Atypical Hemolytic Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 12:20:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA